|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
EP2826860B1
(en)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
CA2909733C
(en)
|
2013-04-18 |
2023-10-17 |
Fondazione Telethon |
Effective delivery of large genes by dual aav vectors
|
|
US11136557B2
(en)
|
2013-05-31 |
2021-10-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
WO2015048534A1
(en)
|
2013-09-26 |
2015-04-02 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
EP4410805A3
(en)
|
2014-03-18 |
2024-11-27 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
IL248102B
(en)
*
|
2014-05-02 |
2022-07-01 |
Genzyme Corp |
aav vectors for gene therapy of the central nervous system and retina
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
AU2015335923B2
(en)
|
2014-10-21 |
2021-04-29 |
University Of Massachusetts |
Recombinant AAV variants and uses thereof
|
|
SG11201703148TA
(en)
|
2014-11-05 |
2017-05-30 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CN119876138A
(zh)
|
2014-11-14 |
2025-04-25 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
CA3193811A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CA2969145A1
(en)
*
|
2014-11-26 |
2016-06-02 |
The Regents Of The University Of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
BR112018003665A2
(en)
*
|
2015-09-28 |
2018-09-25 |
The University Of North Carolina At Chapel Hill |
methods and compositions for antibody evasion viral vectors
|
|
CA3002980A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017070476A2
(en)
|
2015-10-22 |
2017-04-27 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav3 capsid library
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
GB201519086D0
(en)
*
|
2015-10-28 |
2015-12-09 |
Syncona Partners Llp |
Gene Therapy
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
PE20231949A1
(es)
*
|
2015-10-30 |
2023-12-05 |
Spark Therapeutics Inc |
VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
|
|
RU2021102893A
(ru)
|
2015-11-05 |
2021-03-03 |
Бамбу Терапьютикс, Инк. |
Модифицированные гены атаксии фридрейха и векторы для генной терапии
|
|
WO2017096162A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
|
KR102423442B1
(ko)
*
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
BR112018011975A2
(pt)
*
|
2015-12-14 |
2018-12-11 |
Univ Pennsylvania |
composições úteis no tratamento de atrofia muscular espinhal
|
|
WO2017136536A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
US11060088B2
(en)
|
2016-02-12 |
2021-07-13 |
University Of Massachusetts |
Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
|
|
WO2017147477A1
(en)
*
|
2016-02-26 |
2017-08-31 |
University Of Florida Research Foundation, Inc. |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
JP7046828B2
(ja)
|
2016-04-15 |
2022-04-04 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
滲出型加齢性黄斑変性の治療のための組成物
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
CA3024449A1
(en)
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
CA3024448C
(en)
|
2016-05-18 |
2025-09-09 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
MA44546B1
(fr)
*
|
2016-06-15 |
2021-03-31 |
Univ California |
Virus adéno-associés variants et procédés d'utilisation
|
|
CA2971303C
(en)
|
2016-06-21 |
2026-03-03 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
EP3478828B1
(en)
|
2016-06-29 |
2024-09-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
|
JP7305534B2
(ja)
|
2016-07-06 |
2023-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛関連障害を処置するための物質及び方法
|
|
AU2017292173B2
(en)
|
2016-07-06 |
2022-01-13 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
US11458211B2
(en)
|
2016-07-12 |
2022-10-04 |
The University Of Manchester |
Gene therapy
|
|
EP3827812B1
(en)
|
2016-07-29 |
2025-10-29 |
The Regents of the University of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
US20190262373A1
(en)
*
|
2016-08-16 |
2019-08-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
EP3518985A4
(en)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
EP3526333A4
(en)
*
|
2016-10-13 |
2020-07-29 |
University of Massachusetts |
AAV CAPSIDE DESIGNS
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
PT3534922T
(pt)
|
2016-11-04 |
2024-06-07 |
Takeda Pharmaceuticals Co |
Formulações de vírus adenoassociado
|
|
CA3049915A1
(en)
|
2017-01-31 |
2018-08-09 |
Stephen YOO |
Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
|
|
AU2018224044B2
(en)
|
2017-02-21 |
2024-01-25 |
The Uab Research Foundation |
Modified AAV capsid proteins and uses thereof
|
|
WO2018154462A2
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
|
JP2020508056A
(ja)
|
2017-02-22 |
2020-03-19 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ |
遺伝子編集のための組成物および方法
|
|
US20200040061A1
(en)
|
2017-02-22 |
2020-02-06 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
|
US11559588B2
(en)
|
2017-02-22 |
2023-01-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
|
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
JP2020516291A
(ja)
|
2017-04-14 |
2020-06-11 |
レジェンクスバイオ インコーポレーテッド |
ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸−２−スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
WO2018208972A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
CN110831611A
(zh)
*
|
2017-05-10 |
2020-02-21 |
马萨诸塞眼科耳科诊所 |
用于修饰病毒的组装活化蛋白(aap)依赖性的方法和组合物
|
|
JP7330899B2
(ja)
|
2017-05-10 |
2023-08-22 |
マサチューセッツ アイ アンド イヤー インファーマリー |
ウイルスのアセンブリ活性化タンパク質（ａａｐ）依存性を改変する方法および組成物
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
WO2019006182A1
(en)
*
|
2017-06-30 |
2019-01-03 |
The Regents Of The University Of California |
VIRIONS OF ADENO-ASSOCIATED VIRUSES OF CAPSID VARIANTS AND METHODS OF USE THEREOF
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
JP7221275B2
(ja)
*
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖを送達するための組成物および方法
|
|
MX2020002148A
(es)
*
|
2017-08-25 |
2020-07-20 |
Ovid Therapeutics Inc |
Vectores adenoasociados recombinantes.
|
|
JP2020534788A
(ja)
|
2017-08-28 |
2020-12-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルスカプシド変異体及びその使用方法
|
|
CA3075643A1
(en)
|
2017-09-22 |
2019-03-28 |
University Of Massachusetts |
Sod1 dual expression vectors and uses thereof
|
|
US20200263199A1
(en)
|
2017-09-29 |
2020-08-20 |
Voyager Therapeutics, Inc. |
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
BR112020007405A2
(pt)
*
|
2017-10-18 |
2020-12-08 |
Regenxbio Inc. |
Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
|
|
WO2019123429A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a
|
|
WO2019123430A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
|
US12558434B2
(en)
|
2018-02-20 |
2026-02-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
CN118373887A
(zh)
*
|
2018-03-16 |
2024-07-23 |
国家儿童医院研究所 |
通过衣壳修饰增加组织特异性的基因递送
|
|
US20210032660A1
(en)
*
|
2018-03-29 |
2021-02-04 |
Asklepios Biopharmaceutical, Inc. |
Liver tropic recombinant aav6 vectors that evade neutralization
|
|
CA3094465A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
US20210363191A1
(en)
|
2018-04-03 |
2021-11-25 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
CN112543766A
(zh)
|
2018-04-03 |
2021-03-23 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
CN108660159B
(zh)
*
|
2018-04-12 |
2020-10-30 |
四川大学 |
重组蝙蝠腺相关病毒载体及其用途
|
|
KR102051393B1
(ko)
|
2018-05-04 |
2019-12-04 |
(주)지뉴인텍 |
아데노부속바이러스 기반 유전자 전달용 재조합 벡터 및 이를 이용한 암질환 예방 또는 치료용 조성물
|
|
US12338267B2
(en)
|
2018-05-15 |
2025-06-24 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
SG11202011296VA
(en)
|
2018-05-15 |
2020-12-30 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of parkinson's disease
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
AU2019299964A1
(en)
|
2018-07-11 |
2021-01-21 |
Takeda Pharmaceutical Company Limited |
AAV compositions
|
|
JP2021533126A
(ja)
*
|
2018-07-31 |
2021-12-02 |
コーネル・ユニバーシティーCornell University |
臓器機能を制御するための遺伝子治療方法
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
EP3861010A1
(en)
|
2018-10-02 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
WO2020102645A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus for treating pompe disease
|
|
GB201900702D0
(en)
*
|
2019-01-18 |
2019-03-06 |
Univ Bristol |
Therapy
|
|
JP2022522995A
(ja)
|
2019-01-18 |
2022-04-21 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖ粒子を生成するための方法及びシステム
|
|
US11718834B2
(en)
*
|
2019-02-15 |
2023-08-08 |
Sangamo Therapeutics, Inc. |
Compositions and methods for producing recombinant AAV
|
|
BR112021018776A2
(pt)
|
2019-03-21 |
2021-11-30 |
Stridebio Inc |
Vetores de vírus adenoassociado recombinante
|
|
JP7455138B2
(ja)
*
|
2019-03-28 |
2024-03-25 |
ペキン シャオミ モバイル ソフトウェア カンパニー， リミテッド |
コアページング処理
|
|
CN114450411A
(zh)
|
2019-04-01 |
2022-05-06 |
特纳亚治疗股份有限公司 |
具有工程化衣壳的腺相关病毒
|
|
CN114127088B
(zh)
*
|
2019-04-23 |
2024-05-14 |
国家医疗保健研究所 |
变体衣壳蛋白和腺相关病毒aav变体及其药物组合物
|
|
AU2020263757B2
(en)
|
2019-04-24 |
2025-08-28 |
Takara Bio Inc. |
AAV mutant having brain-targeting property
|
|
EP3959227A1
(en)
*
|
2019-04-26 |
2022-03-02 |
The University of North Carolina at Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3990030A1
(en)
|
2019-06-27 |
2022-05-04 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
EP3990636A1
(en)
|
2019-06-28 |
2022-05-04 |
CRISPR Therapeutics AG |
Materials and methods for controlling gene editing
|
|
AU2020299026A1
(en)
*
|
2019-07-04 |
2022-01-20 |
Children's Medical Research Institute |
Methods and AAV vectors for in vivo transduction
|
|
WO2021009805A1
(ja)
*
|
2019-07-12 |
2021-01-21 |
株式会社遺伝子治療研究所 |
ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
|
PL3999119T3
(pl)
*
|
2019-07-15 |
2025-02-10 |
Meiragtx Uk Ii Limited |
Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
|
|
JP7785352B2
(ja)
*
|
2019-08-14 |
2025-12-15 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
遺伝子治療のためのａａｖカプシドバリアント
|
|
WO2021041489A1
(en)
*
|
2019-08-29 |
2021-03-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral vectors for crossing the human blood brain barrier
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
CN114787179A
(zh)
*
|
2019-10-10 |
2022-07-22 |
坚固生物科技公司 |
经修饰的aav衣壳及其用途
|
|
US20220403414A1
(en)
*
|
2019-10-16 |
2022-12-22 |
Wuxi Apptec (Shanghai) Co., Ltd. |
Novel aav variant
|
|
KR20220083714A
(ko)
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
|
|
EP4055030A4
(en)
|
2019-11-08 |
2024-05-22 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
|
US20210261625A1
(en)
*
|
2020-01-29 |
2021-08-26 |
Genzyme Corporation |
Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
|
|
MX2022012752A
(es)
|
2020-04-15 |
2023-01-16 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|
|
CN116096734A
(zh)
|
2020-05-13 |
2023-05-09 |
沃雅戈治疗公司 |
Aav衣壳的向性的重定向
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
GB202010009D0
(en)
*
|
2020-06-30 |
2020-08-12 |
Syncona Investment Man Ltd |
Vector
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
CN111825772B
(zh)
*
|
2020-07-30 |
2023-10-20 |
中国科学院精密测量科学与技术创新研究院 |
具有变异衣壳蛋白的腺相关病毒及其应用
|
|
EP4192961A2
(en)
|
2020-08-06 |
2023-06-14 |
Fundacion para la Investigacion Medica Aplicada |
Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
|
|
TWI902867B
(zh)
|
2020-08-12 |
2025-11-01 |
比利時商Ｕｃｂ生物製藥公司 |
基因療法
|
|
EP4200408A1
(en)
|
2020-08-19 |
2023-06-28 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus vectors for treatment of rett syndrome
|
|
US20230321220A1
(en)
*
|
2020-08-28 |
2023-10-12 |
Joint Stock Company "Biocad" |
Aav5-based vaccine against sars-cov-2
|
|
CN112194706B
(zh)
*
|
2020-09-30 |
2022-03-08 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
US20230381341A1
(en)
*
|
2020-10-07 |
2023-11-30 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
IL301675A
(en)
|
2020-10-09 |
2023-05-01 |
Tenaya Therapeutics Inc |
Methods and preparations for placophilin-2 gene therapy
|
|
IL301255A
(en)
|
2020-10-09 |
2023-05-01 |
UCB Biopharma SRL |
Nucleic acid structures, viral vectors and viral particles
|
|
ES3001131T3
(es)
|
2020-10-28 |
2025-03-04 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para la unión dual de glicanos al vector de AAV2.5
|
|
WO2022093769A1
(en)
*
|
2020-10-28 |
2022-05-05 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
JP2023548816A
(ja)
|
2020-11-03 |
2023-11-21 |
ファイザー・インク |
陰イオン交換クロマトグラフィーによるａａｖベクターの精製方法
|
|
CA3201533A1
(en)
|
2020-11-11 |
2022-05-19 |
European Molecular Biology Laboratory |
Modified viral particles for gene therapy
|
|
US20240052322A1
(en)
|
2020-12-15 |
2024-02-15 |
Pfizer Inc. |
HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
|
|
CA3205588A1
(en)
|
2020-12-21 |
2022-06-30 |
Pfizer Inc. |
Methods and systems for improved cell transfection
|
|
JP2024503234A
(ja)
|
2020-12-23 |
2024-01-25 |
ファイザー・インク |
親和性クロマトグラフィーによるａａｖベクターの精製方法
|
|
BR112023016075A2
(pt)
|
2021-02-10 |
2023-11-21 |
Regenxbio Inc |
Método para tratar hepatoesplenomegalia, método de distribuição de um raav que codifica hids, método para tratar um sujeito humano, método de tratamento de um sujeito humano, método para determinar a eficácia do tratamento, método para identificar um sujeito como tendo mps ii
|
|
GB202101958D0
(en)
|
2021-02-12 |
2021-03-31 |
Ucl Business Ltd |
Gene therapy for dopamine transporter deficiency syndrome
|
|
CN112961219B
(zh)
*
|
2021-02-24 |
2022-08-12 |
中国农业科学院生物技术研究所 |
重组腺相关病毒、其突变体及其构建方法和应用
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
WO2022208342A1
(en)
|
2021-04-01 |
2022-10-06 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
CN117377500A
(zh)
|
2021-04-26 |
2024-01-09 |
阿雷克森国际制药有限公司 |
具有改善的组织向性的腺相关病毒载体衣壳
|
|
WO2022235780A1
(en)
*
|
2021-05-07 |
2022-11-10 |
Oyster Point Pharma, Inc. |
Aav virion encoding neurotrophic factor and uses thereof
|
|
MX2023013393A
(es)
|
2021-05-12 |
2023-12-08 |
Fond Telethon |
Sistema de vectores.
|
|
MX2023015329A
(es)
|
2021-06-22 |
2024-01-23 |
Pfizer |
Produccion de vector de virus adeno-asociado en celulas de insecto.
|
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
|
CN118660710A
(zh)
|
2021-10-20 |
2024-09-17 |
罗切斯特大学 |
用于年龄相关白质损失的竞争性治疗的分离神经胶质祖细胞
|
|
US20240417434A1
(en)
|
2021-10-28 |
2024-12-19 |
UCB Biopharma SRL |
Nucleic acid constructs, viral vectors and viral particles
|
|
MX2024004936A
(es)
|
2021-11-02 |
2024-05-08 |
Voyager Therapeutics Inc |
Variantes de capsides de aav y sus usos.
|
|
EP4426331A1
(en)
|
2021-11-02 |
2024-09-11 |
University of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
IL313832A
(en)
*
|
2021-12-28 |
2024-08-01 |
Chengdu Origen Biotechnology Co Ltd |
Modified AAV capsid protein and its use
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
CN118660913A
(zh)
|
2022-02-21 |
2024-09-17 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
|
CN119562762A
(zh)
|
2022-04-04 |
2025-03-04 |
加利福尼亚大学董事会 |
遗传互补组合物和方法
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
AR129843A1
(es)
*
|
2022-07-06 |
2024-10-02 |
Voyager Therapeutics Inc |
Variantes de la cápside de aav y usos de estas
|
|
US20260041792A1
(en)
*
|
2022-07-12 |
2026-02-12 |
University Of Florida Research Foundation, Incorporated |
Novel aav3b capsid variants with enhanced hepatocyte tropism
|
|
KR20240014846A
(ko)
*
|
2022-07-26 |
2024-02-02 |
숙명여자대학교산학협력단 |
Aav2-anks1a 재조합 바이러스를 포함하는 알츠하이머 질병 치료용 조성물
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
CN116063404B
(zh)
*
|
2022-09-27 |
2025-08-29 |
广州译码基因科技有限公司 |
可提高AAV包装能力的衣壳蛋白MutD及其应用
|
|
GB202216168D0
(en)
|
2022-10-31 |
2022-12-14 |
UCB Biopharma SRL |
Route of administration
|
|
CN116041443B
(zh)
*
|
2022-12-30 |
2023-09-22 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
CN115925819B
(zh)
*
|
2022-12-30 |
2023-10-13 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
AU2024206544A1
(en)
*
|
2023-01-05 |
2025-07-03 |
Emugen Therapeutics Llc |
Chimeric aav and uses thereof
|
|
WO2024163747A2
(en)
|
2023-02-02 |
2024-08-08 |
University Of Rochester |
Competitive replacement of glial cells
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4680752A1
(en)
|
2023-03-14 |
2026-01-21 |
UCB Biopharma SRL |
Gene therapy
|
|
GB202304767D0
(en)
*
|
2023-03-30 |
2023-05-17 |
Ucl Business Ltd |
Synthetic AAV Capsid
|
|
WO2024238853A1
(en)
*
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
AU2024301706A1
(en)
|
2023-07-21 |
2026-02-05 |
Crispr Therapeutics Ag |
Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
|
|
WO2025040166A1
(zh)
|
2023-08-23 |
2025-02-27 |
上海瑞宏迪医药有限公司 |
药物组合物及其用途
|
|
TW202528335A
(zh)
*
|
2023-08-31 |
2025-07-16 |
美商戴諾治療公司 |
衣殼多肽及其使用方法(一)
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
CN118440161B
(zh)
*
|
2024-01-16 |
2025-02-25 |
沈阳兴齐眼药股份有限公司 |
提高aav病毒视网膜穿透能力的衣壳蛋白突变体及其应用
|
|
WO2025186726A1
(en)
|
2024-03-05 |
2025-09-12 |
Crispr Therapeutics Ag |
Modulating expression of agt (angiotensinogen) gene
|
|
WO2025228976A1
(en)
|
2024-04-29 |
2025-11-06 |
UCB Biopharma SRL |
Gene therapy
|
|
GB202407038D0
(en)
|
2024-05-17 |
2024-07-03 |
Axovia Therapeutics Ltd |
Novel Gene Therapy
|
|
WO2025250457A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Enhanced brain transduction by gene therapeutics
|
|
WO2025262203A1
(en)
|
2024-06-21 |
2025-12-26 |
UCB Biopharma SRL |
Nucleic acid sequences
|
|
WO2026017965A1
(en)
|
2024-07-19 |
2026-01-22 |
The University Court Of The University Of Edinburgh |
Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions
|